An overview of the research progress of BRCA gene mutations in breast cancer

被引：16

作者：

Wan, Andi ^{[1
]}

Zhang, Guozhi ^{[1
]}

Ma, Dandan ^{[1
]}

Zhang, Yi ^{[1
]}

Qi, Xiaowei ^{[1
]}

机构：

[1] Army Med Univ, Southwest Hosp, Dept Breast & Thyroid Surg, Chongqing, Peoples R China

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2023年 / 1878卷 / 04期

关键词：

BRCA gene; Breast cancer; Breast conserving surgery; Platinum drugs; PARP inhibitors; CONTRALATERAL PROPHYLACTIC MASTECTOMY; PATHOLOGICAL COMPLETE RESPONSE; STANDARD NEOADJUVANT CHEMOTHERAPY; RECOMBINATION DEFICIENCY HRD; DNA-DAMAGE RESPONSE; GERMLINE MUTATIONS; PHASE-II; FAMILY-HISTORY; CHINESE WOMEN; RISK;

D O I：

10.1016/j.bbcan.2023.188907

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene, including BRCA1 and BRCA2, a biomarker that assesses the risk of breast cancer and influences a patient's individualized treatment options. BRCA1/2 mutation (BRCAm) increases the risk of breast cancer. However, breast-conserving surgery is still an option for BRCAm, and prophylactic mastectomy and nipple-sparing mastectomy may also reduce the risk of breast cancer. BRCAm is sensitive to Poly (ADP-ribose) polymerase inhibitor (PARPi) therapy due to specific types of DNA repair defects, and its combination with other DNA damage pathway inhibitors and endocrine therapy and immunotherapy are also used for the treatment of BRCAm breast cancer. The current treatment and research progress of BRCA1/2 mutant breast cancer in this review provides a basis for the individualized treatment of patients with this type of breast cancer.

引用

页数：11

共 148 条

[31]

Drewett L, 2022, J CLIN ONCOL, V40

[32]

Dufloth Rozany Mucha, 2005, Sao Paulo Med. J., V123, P192, DOI 10.1590/S1516-31802005000400007

[33] Genetic testing in a cohort of young patients with HER2-amplified breast cancer [J].

Eccles, D. M. ;

Li, N. ;

Handwerker, R. ;

Maishman, T. ;

Copson, E. R. ;

Durcan, L. T. ;

Gerty, S. M. ;

Jones, L. ;

Evans, D. G. ;

Haywood, L. ;

Campbell, I. .

ANNALS OF ONCOLOGY, 2016, 27 (03) :467-473

[34] IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab plus nab-paclitaxel in patients with treatment-naive, locally advanced or metastatic triple-negative breast cancer [J].

Emens, L. A. ;

Loi, S. ;

Rugo, H. S. ;

Schneeweiss, A. ;

Dieras, V. ;

Iwata, H. ;

Barrios, C. H. ;

Nechaeva, M. ;

Molinero, L. ;

Duc, A. Nguyen ;

Funke, R. ;

Chui, S. Y. ;

Husain, A. ;

Winer, E. P. ;

Adams, S. ;

Schmid, P. .

CANCER RESEARCH, 2019, 79 (04)

[35] Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) [J].

Fasching, P. A. ;

Link, T. ;

Hauke, J. ;

Seither, F. ;

Jackisch, C. ;

Klare, P. ;

Schmatloch, S. ;

Hanusch, C. ;

Huober, J. ;

Stefek, A. ;

Seiler, S. ;

Schmitt, W. D. ;

Uleer, C. ;

Doering, G. ;

Rhiem, K. ;

Schneeweiss, A. ;

Engels, K. ;

Denkert, C. ;

Schmutzler, R. K. ;

Hahnen, E. ;

Untch, M. ;

Burchardi, N. ;

Blohmer, J-U ;

Loibl, S. .

ANNALS OF ONCOLOGY, 2021, 32 (01) :49-57

[36] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].

FORD, D ;

EASTON, DF ;

BISHOP, DT ;

NAROD, SA ;

GOLDGAR, DE ;

HAITES, N ;

MILNER, B ;

ALLAN, L ;

PONDER, BAJ ;

PETO, J ;

SMITH, S ;

STRATTON, M ;

LENOIR, GM ;

FEUNTEUN, J ;

LYNCH, H ;

ARASON, A ;

BARKARDOTTIR, R ;

EGILSSON, V ;

BLACK, DM ;

KELSELL, D ;

SPURR, N ;

DEVILEE, P ;

CORNELISSE, CJ ;

VARSEN, H ;

BIRCH, JM ;

SKOLNICK, M ;

SANTIBANEZKOREF, MS ;

TEARE, D ;

STEEL, M ;

PORTER, D ;

COHEN, BB ;

CAROTHERS, A ;

SMYTH, E ;

WEBER, B ;

NEWBOLD, B ;

BOEHNKE, M ;

COLLINS, FS ;

CANNONALBRIGHT, LA ;

GOLDGAR, D .

LANCET, 1994, 343 (8899) :692-695

[37] BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients [J].

Friedlaender, Alex ;

Vuilleumier, Aurelie ;

Viassolo, Valeria ;

Ayme, Aurelie ;

De Talhouet, Solene ;

Combes, Jean-Damien ;

Peron, Julien ;

Bodmer, Alexandre ;

Giraud, Sophie ;

Buisson, Adrien ;

Bonadona, Valerie ;

Gauchat-Bouchardy, Isabelle ;

Tredan, Olivier ;

Chappuis, Pierre O. ;

Labidi-Galy, S. Intidhar .

BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (03) :775-783

[38]

Ganz P.A, 2023, QUALITY LIFE RESULTS

[39] Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis [J].

Gelmon, Karen A. ;

Fasching, Peter A. ;

Couch, Fergus J. ;

Balmana, Judith ;

Delaloge, Suzette ;

Labidi-Galy, Intidhar ;

Bennett, James ;

McCutcheon, Susan ;

Walker, Graham ;

O'Shaughnessy, Joyce .

EUROPEAN JOURNAL OF CANCER, 2021, 152 :68-77

[40] Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial [J].

Geyer, C. E. ;

Sikov, W. M. ;

Huober, J. ;

Rugo, H. S. ;

Wolmark, N. ;

O'Shaughnessy, J. ;

Maag, D. ;

Untch, M. ;

Golshan, M. ;

Lorenzo, J. Ponce ;

Metzger, O. ;

Dunbar, M. ;

Symmans, W. F. ;

Rastogi, P. ;

Sohn, J. H. ;

Young, R. ;

Wright, G. S. ;

Harkness, C. ;

McIntyre, K. ;

Yardley, D. ;

Loibl, S. .

ANNALS OF ONCOLOGY, 2022, 33 (04) :384-394

← 1 2 3 4 5 6 7 8 9 10 →